Dishman Carbogen Q4 FY26 Results Earnings Outlook

Wed Mar 18 2026

Dishman Carbogen Amcis Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Dishman Carbogen Amcis was listed on the National Stock Exchange (NSE) on 21-Sep-2017. Dishman Carbogen Amcis share has its face value of 2 per share, and its NSE symbol is DCAL. The company operates in the Pharma sector and primarily belongs to the CRAMS industry.

Table of Contents

Dishman Carbogen Amcis Q4 Results 2026 Preview

Dishman Carbogen Amcis Q4 FY26 revenue is expected to be around Strong Growth, representing a 17% YoY increase compared to the same quarter last year.
Profit After Tax, or PAT, is projected to rise 16% YoY.
EBITDA to rise 15%.
Dishman Carbogen Amcis is expected to show Strong Growth in its revenue.

Click and Sign Up to Get Live Updates on Q4 Results

Dishman Carbogen Amcis Share Performance

Over the past six months, Dishman Carbogen Amcis share price has Positive by 13% to .
Moreover, over the past year, the stock has Positive by 21%
Despite this weak short-term performance, Dishman Carbogen Amcis stock has delivered a financially sound 85% return over the past 5 years.
As of today, 17-03-2026, the Dishman Carbogen Amcis share price is trading at per share.

Key Factors to Watch for Dishman Carbogen Amcis Q4 Results FY26

Revenue Growth & Segment Performance – Focus on topline growth in the CRAMS industry within the Pharma sector.
Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

About Dishman Carbogen Amcis

Dishman Carbogen operates in CRAMS and pharma outsourcing benefiting from global demand and strong client relationships.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts

Dishman Carbogen Amcis is gear up to announce its Q4 FY26 results. Analysts expect 17% revenue growth, a 16% rise in PAT, and a 15% rise in EBITDA. Dishman Carbogen Amcis focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Dishman Carbogen Amcis Q4 results FY26.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.